Nature Publication from Agios Scientists and Co-founder Reinforces Link Between Key Metabolic Enzyme IDH and Cancer Read more about Nature Publication from Agios Scientists and Co-founder Reinforces Link Between Key Metabolic Enzyme IDH and Cancer
Agios Pharmaceuticals, Inc. and The University of Pennsylvania Announce New Collaboration Read more about Agios Pharmaceuticals, Inc. and The University of Pennsylvania Announce New Collaboration
The University of Pennsylvania, The Abramson Family Cancer Research Institute at the Abramson Cancer Center of UPenn, Craig Thompson, M.D., Agios Pharmaceuticals and Celgene Corporation Announce Resolution of Lawsuits Read more about The University of Pennsylvania, The Abramson Family Cancer Research Institute at the Abramson Cancer Center of UPenn, Craig Thompson, M.D., Agios Pharmaceuticals and Celgene Corporation Announce Resolution of Lawsuits
Agios Pharmaceuticals to Present at the UBS Global Life Sciences Conference Read more about Agios Pharmaceuticals to Present at the UBS Global Life Sciences Conference
New Publications from Agios Scientists and Collaborators Reveal Unexpected Regulation of Metabolic Pathways in Cancer Read more about New Publications from Agios Scientists and Collaborators Reveal Unexpected Regulation of Metabolic Pathways in Cancer
Agios Publication Identifies First PotentInhibitors of Mutant IDH1 that Lower Tumor Oncometabolite Read more about Agios Publication Identifies First PotentInhibitors of Mutant IDH1 that Lower Tumor Oncometabolite
Agios Pharmaceuticals, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference Read more about Agios Pharmaceuticals, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference
Target Cancer Metabolism Conference to Feature Three Presentations by Agios Scientists Read more about Target Cancer Metabolism Conference to Feature Three Presentations by Agios Scientists
Agios Pharmaceuticals to Present at the Leerink Swann 2013 Global Healthcare Conference Read more about Agios Pharmaceuticals to Present at the Leerink Swann 2013 Global Healthcare Conference
New Publication in Science Shows That Agios IDH1 Inhibitor Can Reverse Cancer-Causing Effects of Oncometabolite 2HG in Leukemia Model Read more about New Publication in Science Shows That Agios IDH1 Inhibitor Can Reverse Cancer-Causing Effects of Oncometabolite 2HG in Leukemia Model